The over-activation of Lck makes this type of genetic alteration of PAX5 (included in Philadelphia chromosome-like (Ph-Like) B-ALL) possibly eligible for specific target therapy, such as Lck-inhibitors [58]. The gene discussed is PAX5; the disease is acute lymphoblastic leukemia.